Abstract:Glioblastoma is the most frequent and malignant primary brain neoplasm. Glioblastoma growth is promoted by alterations in mediators from five major pathways: MAPK and PI3K canonical growth pathways, telomere elongation/TERT, cell cycle G1-phase and the p53 pathway. In a recent breakthrough study on a prospective Discovery cohort, I proposed the first all-inclusive molecular classification of glioblastoma into seven subgroups, G1-G7, based on MAPK pathway activation. New data from a subsequent, prospective Validation cohort validated the G1-G7 molecular subgroup classification, showing significant demographic and molecular differences between subgroups. Beside the initial histologic diagnosis, the G1-G7 classification requires next generation sequencing (NGS) of formalin-fixed paraffin-embeded (FFPE) samples and genomic-transcriptomic correlations between DNA mutations, copy number variations (CNVs) and RNA expression. Thus, in the Combined cohort containing tumors from over 220 glioblastoma patients, aproximately 75% of cases fell into three major subgroups, G1/EGFR, G3/NF1 and G7/Other, whereas the rest of 25% cases made up the four minor subgroups, G2/FGFR3, G4/RAF, G5/PDGFRA and G6/Multi-RTK. The name of the mutated most upstream, non-redundant, MAPK pathway effector corresponds to each subgroup, except for the G7/Other subgroup in which MAPK activation is minimal and PI3K pathway activation is dominant. The effectors of the other four pathways may be redundant; however, genomic-transcriptomic correlations showed subgroup specificity, with opposing trends for the G1/EGFR and G7/Other molecular subgroups. This first, all-inclusive, molecular subgroup classification of glioblastoma in a large prospective patient cohort allowed integrated pathway analysis, risk stratification and demographic comparison between Caucasian/White and African-American/Black patients. Most importantly, its implementation into clinical practice opened the avenue to controlled therapeutic approaches.

The Pathobiology of Glioma Tumors

The neurobiology of gliomas: from cell biology to the development of therapeutic approaches

Molecular pathways in the formation of gliomas

Glioma targeted therapy: insight into future of molecular approaches

Genetic and Epigenetic Determinants in Tumor Initiation and Progression of Glioblastoma

Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies

Glial Malignancies

Glioma Subclassifications and Their Clinical Significance

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

Path-06. Translation Into Clinical Practice Of The G1-G7 Molecular Subgroup Classification Of Glioblastoma

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Molecular pathology and clinical implications of diffuse glioma

Advances in computational and translational approaches for malignant glioma

Epigenetic pathways and plasticity in brain tumors

Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.

Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition

Advancing precision medicine in gliomas through single-cell sequencing: unveiling the complex tumor microenvironment